Cao Zhensheng, Zhong Ping, Ruan Xiaoan, Merta Phil, Capobianco John O, Flamm Robert K, Nilius Angela M
Dept. R42A, Infectious Disease Research, Bldg. AP30, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL 60064-6145, USA.
Int J Antimicrob Agents. 2004 Oct;24(4):362-8. doi: 10.1016/j.ijantimicag.2004.04.013.
Cethromycin (ABT-773) is a new ketolide currently in clinical trials, for treatment of community acquired respiratory tract infections. The drug is active in vitro and in vivo against Haemophilus influenzae. In this study, the mechanism of action of cethromycin was investigated in H. influenzae. The drug effect was studied using in vitro transcription-translation and whole cell amino acid incorporation. Both cethromycin and erythromycin inhibit protein synthesis with similar potencies; cethromycin, however, had a prolonged molecular postantibiotic effect (PAE) compared with erythromycin which was consistent with previously reported microbiological data. Ribosome binding assay using ribosomes isolated from H. influenzae NP200 revealed that the ribosome binding affinity of cethromycin was more than 20-fold tighter than that of erythromycin. Studies of binding kinetics showed that the tight binding of cethromycin mainly contributed to the 20-fold slower dissociation from cells. Further studies showed cethromycin had a four-fold faster drug accumulation rate than erythromycin. Therefore, the tight binding of cethromycin with ribosomes likely contributed to the faster drug accumulation, slower dissociation from cells and prolonged molecular PAE of cethromycin for H. influenzae.
塞托霉素(ABT - 773)是一种目前正在进行临床试验的新型酮内酯类药物,用于治疗社区获得性呼吸道感染。该药物在体外和体内对流感嗜血杆菌均有活性。在本研究中,对塞托霉素在流感嗜血杆菌中的作用机制进行了研究。使用体外转录 - 翻译和全细胞氨基酸掺入法研究了药物效果。塞托霉素和红霉素抑制蛋白质合成的效力相似;然而,与红霉素相比,塞托霉素具有更长的分子抗生素后效应(PAE),这与先前报道的微生物学数据一致。使用从流感嗜血杆菌NP200分离的核糖体进行的核糖体结合试验表明,塞托霉素的核糖体结合亲和力比红霉素强20多倍。结合动力学研究表明,塞托霉素的紧密结合主要导致其从细胞中解离的速度慢20倍。进一步研究表明,塞托霉素的药物积累速率比红霉素快四倍。因此,塞托霉素与核糖体的紧密结合可能导致其药物积累更快、从细胞中解离更慢以及对流感嗜血杆菌的分子PAE延长。